Your session is about to expire
← Back to Search
Zanubrutinib + Anti-CD20 for Lymphoma (MAHOGANY Trial)
MAHOGANY Trial Summary
This trial will compare the effectiveness of two different drug combinations in people with a certain type of lymphoma that has come back or does not respond to treatment.
MAHOGANY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMAHOGANY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 41 Patients • NCT03145064MAHOGANY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My bone marrow, liver, and kidneys are functioning well.I need medication for my follicular lymphoma or marginal zone lymphoma.You have a medical condition that can be measured by a CT scan or MRI.I've had treatment including an anti-CD20 agent but my cancer did not improve or got worse.My cancer is a type of lymphoma confirmed by tissue analysis.
- Group 1: Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab
- Group 2: Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab
- Group 3: Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab
- Group 4: Follicular Lymphoma Arm B: Lenalidomide plus Rituximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
When was Zanubrutinib cleared by the FDA?
"Zanubrutinib's safety is estimated to be a 3. This is because it is a Phase 3 trial, meaning that Zanubrutinib's efficacy has been supported by some data and its safety has been supported by multiple rounds of data."
Zanubrutinib is most often recommended for what treatments?
"Zanubrutinib is a common treatment for diffuse large b-cell lymphoma (dlbcl). Additionally, this medication can be used to treat other b-cell lymphomas, as well as patients that have undergone two or more prior systemic chemotherapy treatments."
Are there still opportunities to participate in this research?
"The trial is currently looking for participants, with the postings on clinicaltrials.gov indicating that the study is still open. The original posting was on March 10th, 2022, with the most recent update on October 5th, 2022."
Share this study with friends
Copy Link
Messenger